> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CR Pharmaceutical Commercial opens RMB 5.5b equity raise as hospital rules shift cash cycles
- URL: https://chinapharmadesk.com/cr-pharma-commercial-55b-cbex-equity-raise/
- Published: 2026-11-21T11:19:35.000Z
- Updated: 2026-11-21T11:19:36.000Z
- Description: China Resources Pharmaceutical (HKEX: 03320) launched CBEX bidding (G62026BJ1000075-0) on Nov 20, 2026 for CR Pharmaceutical Commercial to raise up to RMB 5.5b externally plus RMB 2b from Beijing Pharma.
- Author: Lin Yi
- Tags: Desk brief, Capital, Market Access, Regulation

[China Resources Pharmaceutical Group Limited (HKEX: 03320)](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1120/2026112001379.pdf?ref=chinapharmadesk.com) announced via an Inside Information filing on November 20, 2026 that its non-wholly-owned distribution flagship, `CR Pharmaceutical Commercial Group Company Limited`, formally opened public bidding on the China Beijing Equity Exchange (`CBEX`, Project `G62026BJ1000075-0`) to issue up to **RMB 5.5 billion** in new shares to no more than 15 external investors. In addition, wholly-owned subsidiary `Beijing Pharmaceutical Group` holds an option to concurrently subscribe for up to **RMB 2.0 billion** by non-public issuance at the identical external clearing price—putting total potential equity proceeds at **up to RMB 7.5 billion** to fund mergers and acquisitions (`M&A`), logistics infrastructure, and **repayment of outstanding interest-bearing debt**.

While headline announcements frame the transaction as routine growth capital following the October 16 pre-disclosure, cross-checking the `CBEX` filing against [CITIC Securities’ June 2026 bond trustee report (24 Runyao 01 / 25 Runyao 05)](https://gu.sina.cn/bd/hq/notice.php?annid=24820377&ref=chinapharmadesk.com) reveals why China’s third-largest pharmaceutical wholesaler is raising up to RMB 7.5 billion in fresh equity now: public-hospital receivable cycles have stretched `CR Pharmaceutical Commercial`’s total liabilities to **RMB 125.61 billion** (`75.55%` asset-liability ratio) at the exact moment that provincial execution of the [four-ministry Class 1 hospital formulary notice (Guoweiban Yizheng Fa \[2026\] No. 18)](https://chinapharmadesk.com/china-class1-hospital-formulary-policy/) and `NMPA` electronic traceability pilots are shifting more working-capital burden onto Tier-1 national distributors.

## A 6.44% hospital gross margin against RMB 125.61 billion in liabilities

Audited FY2025 bond disclosures for `CR Pharmaceutical Commercial` illustrate the razor-thin margin and working-capital mechanics of China’s public-hospital distribution model:

| Financial & Cap-Table Metric (CR Pharmaceutical Commercial) | FY2024 Audited                                               | FY2025 Audited / Current (CBEX G62026BJ1000075-0)                                     | YoY Change / Structural Detail                                                                                       |
| ----------------------------------------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------- |
| **Total Operating Revenue**                                 | RMB 213.20 billion                                           | **RMB 221.00 billion** (RMB 221,004 million)                                          | **+3.66% YoY**; overall gross margin **6.46%** (\-5 bps)                                                             |
| **Direct Hospital Sales (Yiliao Chunxiao)**                 | RMB 148.20 billion (69.51% share)                            | **RMB 151.42 billion** (**68.51% share**)                                             | Gross margin **6.44%** (+22 bps); core tertiary/secondary hospital supply                                            |
| **Wholesale Distribution (Yiyao Fenxiao) & Retail**         | Wholesale RMB 56.44b (6.45% GM); Retail RMB 7.74b (6.23% GM) | **Wholesale RMB 59.53b** (5.77% GM); **Retail RMB 9.14b** (5.80% GM)                  | Wholesale margin compressed **\-68 bps**; retail revenue grew **+18.07%** (DTP expansion)                            |
| **Net Profit & EBITDA**                                     | Net profit RMB 2.21b (EBITDA RMB 5.81b)                      | **Net profit RMB 2.39 billion** (EBITDA RMB 5.94b)                                    | **1.08% net margin**; attributable net profit RMB 1.87 billion                                                       |
| **Total Assets / Total Liabilities / Debt Ratio**           | Assets RMB 155.93b / Liabilities RMB 120.38b (77.20%)        | **Assets RMB 166.24b / Liabilities RMB 125.61b** (**75.55%**)                         | Total debt / EBITDA **8.08x**; financing cash outflow **\-RMB 8.75 billion**                                         |
| **Accounts-Receivable & Inventory Turnover**                | AR turnover 3.22x (\~113 days); Inventory 7.79x              | **AR turnover 2.86x (\~128 days)**; **Inventory 6.71x**                               | **AR turnover slowed \-11.31% YoY**; **Interest coverage fell \-12.19%** (3.61x to **3.17x**)                        |
| **Pre-Issuance Shareholder Register (CBEX filing)**         | Post-2023 debt-to-equity (Zhaizhuangu) round                 | **CR Pharma (03320.HK) holds 80.13%** (Beijing Pharma 71.05% \+ CR Pharma Inv. 9.08%) | **Big Five bank AICs hold 18.55%** (ICBC, CCB, ABC, BOCOM at 3.78% each + BOC 3.44%), plus PICC 0.76% & Guorui 0.57% |

Because `CR Pharmaceutical Commercial` already brought in the financial asset investment (`AIC`) debt-to-equity arms of China’s Big Five state-owned banks (`ICBC`, `CCB`, `ABC`, `BOCOM`, and `BOC`) for a combined **18.55% stake** during its prior capital round, launching a second `CBEX` equity raise of up to **RMB 5.5 billion** from external institutions (plus up to **RMB 2.0 billion** from `Beijing Pharmaceutical Group` to prevent parent control dilution) underscores how fast working-capital requirements are growing. Even if the full RMB 7.5 billion is raised and applied entirely against liabilities, pro-forma asset-liability leverage on its RMB 166.24 billion balance sheet would ease by roughly 3.3 percentage points to \~`71%–72%`.

## Why hospital formulary loosening and digital traceability favor giant wholesalers

Two regulatory developments over the past ten days explain why `CR Pharmaceutical Commercial` is simultaneously earmarking proceeds for **debt repayment**, **cold-chain/specialty logistics**, and **regional `M&A`**:

1. **Hospital formulary loosening increases distributor working-capital intensity**: Under the four-ministry notice (*Circular on Further Improving the Safe and Rational Equipping and Use of Innovative Drugs*, [Guoweiban Yizheng Fa \[2026\] No. 18](https://wjw.xinjiang.gov.cn/hfpc/zcwj4/202611/1a88184fe9134453a1a872cf3a50ca18.shtml?ref=chinapharmadesk.com), issued October 30 and republished for implementation by provincial health and `NHSA` bureaus in Xinjiang, Shaanxi, Shanghai, and Yunnan between November 11 and November 20), secondary and tertiary public hospitals must convene Pharmacy and Therapeutics (`P&T`) committees to stock [Class 1](https://chinapharmadesk.com/china-pharma-glossary/) drugs from the [2026 NRDL and the 28-drug Commercial Health Insurance Innovative Drug List](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/), exempted from `one-drug-two-specifications` (`yipin lianggui`) caps and per-visit drug-cost growth indicators. Because direct hospital sales (`yiliao chunxiao`) account for **68.51%** of `CR Pharmaceutical Commercial`’s revenue and carry an average collection cycle of **\~128 days (`2.86x` annual turnover)**, onboarding high-unit-price `ADCs`, bispecifics, and rare-disease biologics into public hospitals requires distributors to finance months of upstream manufacturer payables before hospitals settle receivables.
2. **One-click electronic circulation traceability squeezes small wholesalers into `M&A`**: In late September and October 2026, provincial drug regulators in **Jiangxi** (covering 20 pilot enterprises across 7 scenarios) and **Henan** (covering 16 pilot enterprises across 4 baseline scenarios) launched China’s first `one-click penetration` (`yijian chuantou`) electronic drug-circulation supervision pilots—replacing paper batch-release certificates (`yaojian baogao`), shipping manifests (`suihuo tongxing dan`), and first-time vendor qualification dossiers (`shouying ziliao`) with real-time regulatory data feeds. While digital archiving lowers compliance friction for national wholesalers with integrated ERP infrastructure, regional distributors facing both `VBP` price compression and mandatory digital traceability upgrades are increasingly prime `M&A` targets for cash-rich consolidators.

## Next evidence triggers to watch

- **Final `CBEX` bidding close and subscription agreement (`G62026BJ1000075-0`, Q4 2026 – Q1 2027)**: Final subscribed amount against the RMB 5.5 billion external cap, the filed state-owned asset appraisal floor price, whether `Beijing Pharmaceutical Group` exercises its RMB 2.0 billion matching option, and the resulting post-money dilution of `CR Pharma`’s (`03320.HK`) `80.13%` stake.
- **FY2026 bond report working-capital metrics (April–June 2027)**: Whether `CR Pharmaceutical Commercial`’s accounts-receivable turnover (`2.86x` in FY2025) stabilizes as provincial `NHSA` direct-settlement pilots expand alongside the January 1, 2027 implementation of the 2026 `NRDL`.